Yesterday’s upbeat report on consumer spending and income in the US provides fresh support for last week’s moderately hawkish comments from Fed officials, who hinted that another interest rate hike is near, perhaps as early as next month’s Federal Open Market Committee (FOMC) meeting. Yet, support for pricing in a new round of policy tightening is modest at best via Treasury yields. Is that because job growth is expected to slow in this Friday’s employment report for July after two months of strong increases?
Total nonfarm payrolls are on track to rise by a moderate 175,000 in August, according to Econoday.com’s consensus forecast. That’s a decent gain, but it’s well below July’s increase of 255,000 and July’s 292,000 surge. Monthly data is noisy, and so it’s best to focus on the year-over-year trend. The August estimate translates into a 1.74% increase versus the year-earlier level, fractionally above July’s annual pace.
Job growth has clearly slowed in year-over-year terms, which isn’t terribly surprising for an economic recovery that’s celebrated its seventh birthday in June – one of the longest expansions on record, according to NBER data. The question is whether the Fed will feel compelled to continue squeezing rates when the trend for job growth is on a downward trajectory.
stock trading forum: Regeneron Pharmaceuticals, Inc.(REGN)
- [By Ben Levisohn]
Regeneron Pharmaceuticals (REGN) tumbled to the bottom of the S&P 500 today after a judge said the company could be forced to stop selling an anti-cholesterol drug due to violating an Amgen (AMGN) patent.
Agence France-Presse/Getty Images
Regeneron Pharmaceuticalsdropped 5.8% to $358.68 today, while the S&P 500 rose 0.4% to 2,276.98.
Chardan’sGbola Amusa takes a victory lap:
Yesterday, after markets closed, it was announced that US Federal District Court Judge Sue Robinson ruled to issue a permanent injunction against Praluent, the PCSK9 mAb for hypercholesterolemia from partners Regeneron and Sanofi, due to infringement of patents from Amgen. The court has imposed a 30-day suspension (stay) on the injunction to allow for settlement or appeal of the District Court decision. Sanofi and Regeneron have announced their intent to appeal the ruling to the US Court of Appeals for the Federal Circuit (CAFC). The injunction decision is consistent with our counter-consensus published views communicated on 25 January 2016 (“Downgrade to Sell on evidence of likely infringement of Amgen’s PCSK9 patents”) and subsequently. Based on consultation with expert legal counsel, we now put >75% probability Amgen will prevail on appeal and/or Praluent is ultimately removed from the US market, and/or Amgen achieves a settlement substantially in its favor. We currently model $3.3 bn in non-risk-adjusted 2022E US revenues for Praluent, while consensus models $1.2 bn in 2022E US revenues. We reiterate our view from 25 January 2016 to preferentially own Amgen, The Medicines Company (MDCO) (Buy), and Alnylam (ALNY) (Buy) over Regeneron for exposure to PCSK9 inhibitor market dynamics as outcomes trials approach.
While the loss is bad news for Regeneron, Barron’s Johanna Bennettargues that it could herald a comeback for Amgen.
Regeneron’s market capitalization fell to $38.5 billion today from $40.2 bil
- [By Todd Campbell, Demitrios Kalogeropoulos, and Reuben Gregg Brewer]
In the case of these three stocks, however, it may be worth taking a gamble. Our contributors think catalysts at Regeneron Pharmaceuticals (NASDAQ:REGN), Royal Dutch Shell (NYSE:RDS-B), and United Parcel Service (NYSE:UPS) can get them back to their winning ways. Read on to find out if these down-and-out stocks are right for your portfolio.
- [By Ben Levisohn]
Regeneron Pharmaceuticals (REGN) soared to the top of the S&P 500 today after a competitor’s competing drug failed a Phase 3 trial.
Regenerongained 3.8% to $387.10 today, while the S&P 500 declined 0.1% to 2,256.96.
RBC’s Adnan Butt and Michael Yee offer their take:
Two Phase 3 studies comparing Ophthotechs (OPHT) Fovista plus Lucentis to Lucentis alone did not meet the primary endpoint of demonstrating a better vision for the combination at 12 months. The improvements were 10.24 letters for the combo vs. 10.01 for Lucentis when the two Phase 3s were combined. Individually, one Phase 3 showed combo improvement of 10.74 letters vs. 9.82 letters alone and the second 9.91 letters vs. 10.36 letters with Lucentis alone. A third Phase 3 study combining Fovista with Eylea or Avastin is ongoing…
Big overhang removed; [Regeneron] shares should be up and then continue to rise with the focus moving to dupilumab. Overhang was that Fovista success and approval could disrupt the market for Eylea as more docs tried combining nearly free Avastin (off-label) with Fovista to improve outcomes with patients. We had always argued that even under that scenario Eylea would be used since it is the most potent agent. We are buyers at current level especially ahead of the upcoming dupilumab launch.
Regeneron’s market capitalization rose to $51.5 billion today from $39.3 billion yesterday. It reported net income of $636 million on sales of $4.1 billion in 2015.
- [By Chris Lange]
Shares of Amgen Inc. (NASDAQ: AMGN) saw a handy gain to close out the week after the company won a Delaware court ruling that blocked Sanofi (NYSE: SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) from selling their cholesterol-lowering drug in the United States. Essentially the court found that the drug Praluent actually infringed upon Amgens patents for its rival treatment Repatha.
- [By Johanna Bennett]
Shares of biotechnology giant Regeneron Pharmaceuticals (REGN) have climbed more than 4% today after Piper Jaffray analyst Ed Tenthoff upgraded the stock from a neutral to an overweight, with a $446 price target.
The upgrade comes just a few days after the drug maker released soft guidance for 2017 and forecasts called for slowing sales of the eye drug Eylea.
But Piper Jaffrays Tenthoff argues that anticipated approvals and deep pipeline should drive long-term value. Of particular importance: the atopic dermatitis drug Dupixent (dupilumab).
We are confident in FDA approval of Dupixent (dupilumab) in moderate-to-severe atopic dermatitis by the March 29th PDUFA date and in Europe in late 2017. The Phase III LIBERTY ASTHMA QUEST study has fully enrolled 1,858 persistent asthma patients to 200mg and 300mg subcu Dupixent q2W. We look for data this year to enable an sBLA submission by YE:17. Regeneron is conducting two Phase III trials in nasal polyps and will initiate Phase III pediatric atopic dermatitis and asthma trials. The company will report data from a Phase II eosinophilic esophagitis study in 1H:17 and begin a Phase II food allergy study in 2H:17. The FDA has deemed Sanofi’s Le Trait facility “acceptable”. As a result, we anticipate the partners will refile on Kevzara (sarilumab) and could gain approval in 2Q:17. These two launches should turn Regeneron’s antibody alliance with Sanofi profitable.
Todays news is the latest development in what has been a volatile time the drug maker. The shares have fallen sharply over the during the last three months, the result of a patent suit with Amgen (AMGN) over its anti-cholesterol drug Praluent, which a judge had set it wouldnt be able to sell in the U.S. , But last week, a judge granted a stay that would allow Regeneron to sell Praluent. It also fueled a pop in its shares.
The next day, however, Regeneron reported earnings, and while profits o
stock trading forum: Platform Specialty Products Corporation(PAH)
- [By WWW.THESTREET.COM]
In his second “Executive Decision” segment, Cramer spoke with Rakesh Sachdev, CEO of Platform Specialty Products (PAH) , the agriculture and industrial roll-up company which has seen its shares double over the past 12 months. Yesterday, Platform Specialty delivered a two-cents-a-share earnings beat.
- [By Lee Jackson]
Platform Specialty Products Corp. (NYSE: PAH) had a well-known seller parting with a huge chunk of stock. Bill Ackman’s Pershing Square hedge fund sold a total of 2,285,888 shares of the stock at $8.78 apiece. The total for the sale was posted at $20 million.The company produces and sells specialty chemical products in the Americas, the Asia-Pacific and Europe. The stock closed last Friday at $8.52.
stock trading forum: Senior Housing Properties Trust(SNH)
- [By Matthew Frankel]
Healthcare real estate is just as defensive of an investment as net-lease retail, and has even more growth potential in the years ahead. One beaten-down healthcare REIT that I have my eye on in 2017 is Senior Housing Properties Trust (NASDAQ:SNH).
stock trading forum: Siebert Financial Corp.(SIEB)
- [By Jim Robertson]
On Tuesday, our Under the Radar Moversnewsletter suggested shorting small cap discount brokerageSiebert Financial Corp (NASDAQ: SIEB):
Siebert Financial has been on our watchlist for a while, overbought and toying with the idea of a pullback. We’re finally starting to see evidence that the weight of the gain is taking a toll. We’ve seen a string of lower highs following the last bullish gasp from the 9th. We’re going to assume that was the pivot point. (It has been so far, anyway.)
- [By Lisa Levin]
Siebert Financial Corp. (NASDAQ: SIEB) shares shot up 61 percent to $8.30 following news it will offer deeply discounted online trading of U.S. equities next year.
- [By Cameron Saucier]
Siebert (Nasdaq: SIEB) is a holding company that has a retail discount brokerage business through its subsidiary, Muriel Siebert & Co. SIEB rose 60% last month after it announced a purchasing agreement with Kennedy Cabot Acquisition. Under the agreement, Kennedy Cabot will purchase shares of SIEB. SIEB is currently trading at $3.37 per share and is up 157% YOY.
stock trading forum: MannKind Corporation(MNKD)
- [By WWW.MONEYSHOW.COM]
MannKind Corp. (MNKD) has developed a drug, Afrezza, which is a new form of inhalable insulin that is proving to have many benefits over existing mealtime insulins for diabetics.
- [By James E. Brumley]
When most investors think of diabetes stocks, names like Novo Nordisk A/S (ADR) (NYSE:NVO) and MannKind Corporation (NASDAQ:MNKD) come to mind. And well they should. Novo Nordisk is the biggest insulin company in the world, and while MannKind is relatively small, it’s a name that turns heads simply because it came up with an inhalable insulin that – after a slow start – is getting a little traction.
In both cases though, the paradigm is the same one that was first used decades ago. That is, if a person isn’t making their own insulin, then it must be introduced externally. What if instead a diabetic’s glucose levels could be controlled by turning on the cells in their body responsible for processing that sugar? That’s the approach Cell MedX Corp (OTCMKTS:CMXC) is taking, using a relatively new but very compelling science.
While chemical-based manufactured pharmaceuticals were largely the core of healthcare for well over the past century, it’s become clear that our bodies – right down to our cells – are also electrical in nature. Not only do they produce it, they need it to function properly. The FDA has even recently approved a therapeutic device that delivers mild electrical currents to and through an individual’s body as a means of treating pain. This “electromedicine” has also shown a certain degree of efficacy as a treatment for several illnesses, including cancer. Specifically, electrical currents have been demonstrated to force pleomorphic cancer microbes into hibernation, essentially making a cancerous cell a normal, healthy cell again. So, using an electrical current as a means of therapy for diabetics isn’t far-fetched at all. Indeed, it’s quite brilliant.
As for how Cell MedX is using the idea, it’s actually quite simple. The device is called an eBalance. At first glance it just looks like another ordinary tablet computer. A closer inspection of the e-Balance device, however, makes it clear that it’s not just another tablet. It’
- [By Peter Graham]
The Q4 2016 earnings report for troubled small cap diabetes stock MannKind Corporation (NASDAQ: MNKD) is scheduled for after the market closes Thursday (March 16th). So far,MannKind Corporations novel rapid-acting inhaled insulin therapy Afrezza has been a disappointment for investors; and if that doesnt start to change, theMNKD could soon run out of money. For that reason, the Company has elevated short interest of 36.43% according to Highshortinterest.com.
- [By Sean Williams]
Last summer, my mind was fully set on short-selling shares (i.e., betting they go down) of drugmaker MannKind (NASDAQ:MNKD). My investment thesis was pretty straightforward: MannKind was eventually going to seek bankruptcy protection.